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Acromegaly is a chronic disease caused by hypersecretion of growth hormone (GH), most frequently from a 
pituitary somatotropic adenoma. Its prevalence was estimated at 60–70 cases per million people, but in recent years 
it seems to be higher (even 86 cases per million). Approximately 3-4 new cases of acromegaly are annually 
diagnosed per million people. 
In acromegalic patients, the mortality rate is 2-4 times higher than in the general population. The most common 
causes of death in patients in question are cardiovascular and/or respiratory complications, or neoplastic diseases. 
Data indicating the increased risk of the development of benign and malignant tumors of various organs, 
particularly of the colon, thyroid gland, breast, and prostate, are reported in numerous studies. An elevated level of 
IGF-I seems to be responsible for the increased risk of cancers. It is to be recalled that IGF-I is a mitogenic, 
anti-apoptotic and angiogenesis-promoting factor. 
Prevalence of cancers in acromegalic patients remains controversial: some authors describe the increased 
prevalence, in contrast, others do not. The difference among studies may be due to a low incidence of acromegaly 
per se, retrospective nature of studies or to differences in study designs. In most studies, patients with cancers 
diagnosed prior to acromegaly were excluded [1]. 
The presence of IGF-I receptors was shown in both normal and neoplastic thyroid tissue in humans, a long time 
ago. There are numerous scientific evidence that IGF-I reveals an important, TSH–independent effect in growth 
processes in humans thyroid [2, 3]. Moreover, there are a lot of studies describing the increased prevalence of 
goitre (both diffuse and nodular) in acromegalic patients, and many authors have demonstrated a positive 
correlation between the thyroid volume and serum IGF-I concentration. 
Large meta-analysis published recently by Wolinski et al. [4] has confirmed that both thyroid nodular disease and 
thyroid carcinoma are significantly more frequent in acromegalic patients than in general population (Table 1). 
Table 1  Studies with control group included in meta-analysis – the table taken from the study by Wolinski et al. 
[4], modified. Asterisk (*) - persons with non-functioning or Prl secreting adenomas. 
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Accordingly, these results demonstrate that the repeated thyroid ultrasound (US) examination and careful 
evaluation of possible lesions (together with cytological assessment) should be important part of follow-up in 
patients with acromegaly. Wolinski et al. [4] documented that in newer studies on acromegalic subjects, thyroid 
disorders were reported more frequently - in studies published after year 2008, thyroid nodular disease occurred in 
about 65% of patients whereas in older studies approx. in 54%. Similar phenomenon could be recorded in case of 
thyroid carcinomas – 6% patients in newer reports published after 2008 vs. 3% in older studies, published before 
2008. These results speak for the hypothesis that the improvement in diagnostic methods and therapy of 
acromegaly extends the survival time of patients, what - in turn - increases the prevalence of benign and malignant 
neoplasms possible to detect. 
Result of selected studies on acromegaly and thyroid disorders, published in recent years, are presented in Tables 2 
and 3. 
Table 2  Results of the retrospective study by Turkish authors [1], including 64 acromegalic patients who were 





































Table 3  Results of study from Brasil, including 106 acromegalic patients, who were subjected to thyroid US 
examination [5]. In 4 patients (3.8%) thyroid carcinoma was diagnosed in cytological examination (2 cases - 
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